Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries

Autores
García Betancur, Juan Carlos; De La Cadena, Elsa; Mojica, María F.; Hernández Gómez, Cristhian; Correa, Adriana; Radice, Marcela Alejandra; Castañeda Méndez, Paulo; Jaime Villalon, Diego A.; Gales, Ana C.; Munita, José M.; Villegas, María Virginia
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Ceftolozane/tazobactam (C/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against Pseudomonas aeruginosa and tazobactam, a known β-lactamase inhibitor. The aim of this study was to evaluate the activity of C/T against clinical isolates of P. aeruginosa and Enterobacterales collected from five Latin American countries between 2016 and 2017, before its clinical use in Latin America, and to compare it with the activity of other available broad-spectrum antimicrobial agents. Methods: a total of 2760 clinical isolates (508 P. aeruginosa and 2252 Enterobacterales) were consecutively collected from 20 hospitals and susceptibility to C/T and comparator agents was tested and interpreted following the current guidelines. Results: according to the CLSI breakpoints, 68.1% (346/508) of P. aeruginosa and 83.9% (1889/2252) of Enterobacterales isolates were susceptible to C/T. Overall, C/T demonstrated higher in vitro activity than currently available cephalosporins, piperacillin/tazobactam and carbapenems when tested against P. aeruginosa, and its performance in vitro was comparable to fosfomycin. When tested against Enterobacterales, it showed higher activity than cephalosporins and piperacillin/tazobactam, and similar activity to ertapenem. Conclusions: these results show that C/T is an active β-lactam agent against clinical isolates of P. aeruginosa and Enterobacterales.
Fil: García Betancur, Juan Carlos. Universidad El Bosque;
Fil: De La Cadena, Elsa. Universidad El Bosque;
Fil: Mojica, María F.. Universidad El Bosque; . Case Western Reserve University; Estados Unidos
Fil: Hernández Gómez, Cristhian. Universidad El Bosque;
Fil: Correa, Adriana. Universidad Santiago de Cali; Colombia
Fil: Radice, Marcela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquÍmica. Instituto de Investigaciones En Bacteriología y Virología Molecular (IBaViM); Argentina
Fil: Castañeda Méndez, Paulo. Fundacion Clinica Medica Sur; México
Fil: Jaime Villalon, Diego A.. Fundacion Clinica Medica Sur; México
Fil: Gales, Ana C.. Universidade Federal de Sao Paulo; Brasil
Fil: Munita, José M.. Universidad del Desarrollo; Chile
Fil: Villegas, María Virginia. Universidad El Bosque;
Materia
ANTIMICROBIAL RESISTANCE
CEFTOLOZANE/TAZOBACTAM
ENTEROBACTERALES
LATIN AMERICA
PSEUDOMONAS AERUGINOSA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/216748
Acceder
id CONICETDig_1c6cc4d52e8288c0973427e68180c55c
oai_identifier_str oai:ri.conicet.gov.ar:11336/216748
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American CountriesGarcía Betancur, Juan CarlosDe La Cadena, ElsaMojica, María F.Hernández Gómez, CristhianCorrea, AdrianaRadice, Marcela AlejandraCastañeda Méndez, PauloJaime Villalon, Diego A.Gales, Ana C.Munita, José M.Villegas, María VirginiaANTIMICROBIAL RESISTANCECEFTOLOZANE/TAZOBACTAMENTEROBACTERALESLATIN AMERICAPSEUDOMONAS AERUGINOSAhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background: Ceftolozane/tazobactam (C/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against Pseudomonas aeruginosa and tazobactam, a known β-lactamase inhibitor. The aim of this study was to evaluate the activity of C/T against clinical isolates of P. aeruginosa and Enterobacterales collected from five Latin American countries between 2016 and 2017, before its clinical use in Latin America, and to compare it with the activity of other available broad-spectrum antimicrobial agents. Methods: a total of 2760 clinical isolates (508 P. aeruginosa and 2252 Enterobacterales) were consecutively collected from 20 hospitals and susceptibility to C/T and comparator agents was tested and interpreted following the current guidelines. Results: according to the CLSI breakpoints, 68.1% (346/508) of P. aeruginosa and 83.9% (1889/2252) of Enterobacterales isolates were susceptible to C/T. Overall, C/T demonstrated higher in vitro activity than currently available cephalosporins, piperacillin/tazobactam and carbapenems when tested against P. aeruginosa, and its performance in vitro was comparable to fosfomycin. When tested against Enterobacterales, it showed higher activity than cephalosporins and piperacillin/tazobactam, and similar activity to ertapenem. Conclusions: these results show that C/T is an active β-lactam agent against clinical isolates of P. aeruginosa and Enterobacterales.Fil: García Betancur, Juan Carlos. Universidad El Bosque;Fil: De La Cadena, Elsa. Universidad El Bosque;Fil: Mojica, María F.. Universidad El Bosque; . Case Western Reserve University; Estados UnidosFil: Hernández Gómez, Cristhian. Universidad El Bosque;Fil: Correa, Adriana. Universidad Santiago de Cali; ColombiaFil: Radice, Marcela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquÍmica. Instituto de Investigaciones En Bacteriología y Virología Molecular (IBaViM); ArgentinaFil: Castañeda Méndez, Paulo. Fundacion Clinica Medica Sur; MéxicoFil: Jaime Villalon, Diego A.. Fundacion Clinica Medica Sur; MéxicoFil: Gales, Ana C.. Universidade Federal de Sao Paulo; BrasilFil: Munita, José M.. Universidad del Desarrollo; ChileFil: Villegas, María Virginia. Universidad El Bosque;MDPI2022-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/216748García Betancur, Juan Carlos; De La Cadena, Elsa; Mojica, María F.; Hernández Gómez, Cristhian; Correa, Adriana; et al.; Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries; MDPI; Antibiotics; 11; 8; 8-2022; 1-112079-6382CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3390/antibiotics11081101info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:11:41Zoai:ri.conicet.gov.ar:11336/216748instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:11:41.433CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
title Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
spellingShingle Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
García Betancur, Juan Carlos
ANTIMICROBIAL RESISTANCE
CEFTOLOZANE/TAZOBACTAM
ENTEROBACTERALES
LATIN AMERICA
PSEUDOMONAS AERUGINOSA
title_short Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
title_full Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
title_fullStr Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
title_full_unstemmed Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
title_sort Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
dc.creator.none.fl_str_mv García Betancur, Juan Carlos
De La Cadena, Elsa
Mojica, María F.
Hernández Gómez, Cristhian
Correa, Adriana
Radice, Marcela Alejandra
Castañeda Méndez, Paulo
Jaime Villalon, Diego A.
Gales, Ana C.
Munita, José M.
Villegas, María Virginia
author García Betancur, Juan Carlos
author_facet García Betancur, Juan Carlos
De La Cadena, Elsa
Mojica, María F.
Hernández Gómez, Cristhian
Correa, Adriana
Radice, Marcela Alejandra
Castañeda Méndez, Paulo
Jaime Villalon, Diego A.
Gales, Ana C.
Munita, José M.
Villegas, María Virginia
author_role author
author2 De La Cadena, Elsa
Mojica, María F.
Hernández Gómez, Cristhian
Correa, Adriana
Radice, Marcela Alejandra
Castañeda Méndez, Paulo
Jaime Villalon, Diego A.
Gales, Ana C.
Munita, José M.
Villegas, María Virginia
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ANTIMICROBIAL RESISTANCE
CEFTOLOZANE/TAZOBACTAM
ENTEROBACTERALES
LATIN AMERICA
PSEUDOMONAS AERUGINOSA
topic ANTIMICROBIAL RESISTANCE
CEFTOLOZANE/TAZOBACTAM
ENTEROBACTERALES
LATIN AMERICA
PSEUDOMONAS AERUGINOSA
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Ceftolozane/tazobactam (C/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against Pseudomonas aeruginosa and tazobactam, a known β-lactamase inhibitor. The aim of this study was to evaluate the activity of C/T against clinical isolates of P. aeruginosa and Enterobacterales collected from five Latin American countries between 2016 and 2017, before its clinical use in Latin America, and to compare it with the activity of other available broad-spectrum antimicrobial agents. Methods: a total of 2760 clinical isolates (508 P. aeruginosa and 2252 Enterobacterales) were consecutively collected from 20 hospitals and susceptibility to C/T and comparator agents was tested and interpreted following the current guidelines. Results: according to the CLSI breakpoints, 68.1% (346/508) of P. aeruginosa and 83.9% (1889/2252) of Enterobacterales isolates were susceptible to C/T. Overall, C/T demonstrated higher in vitro activity than currently available cephalosporins, piperacillin/tazobactam and carbapenems when tested against P. aeruginosa, and its performance in vitro was comparable to fosfomycin. When tested against Enterobacterales, it showed higher activity than cephalosporins and piperacillin/tazobactam, and similar activity to ertapenem. Conclusions: these results show that C/T is an active β-lactam agent against clinical isolates of P. aeruginosa and Enterobacterales.
Fil: García Betancur, Juan Carlos. Universidad El Bosque;
Fil: De La Cadena, Elsa. Universidad El Bosque;
Fil: Mojica, María F.. Universidad El Bosque; . Case Western Reserve University; Estados Unidos
Fil: Hernández Gómez, Cristhian. Universidad El Bosque;
Fil: Correa, Adriana. Universidad Santiago de Cali; Colombia
Fil: Radice, Marcela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquÍmica. Instituto de Investigaciones En Bacteriología y Virología Molecular (IBaViM); Argentina
Fil: Castañeda Méndez, Paulo. Fundacion Clinica Medica Sur; México
Fil: Jaime Villalon, Diego A.. Fundacion Clinica Medica Sur; México
Fil: Gales, Ana C.. Universidade Federal de Sao Paulo; Brasil
Fil: Munita, José M.. Universidad del Desarrollo; Chile
Fil: Villegas, María Virginia. Universidad El Bosque;
description Background: Ceftolozane/tazobactam (C/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against Pseudomonas aeruginosa and tazobactam, a known β-lactamase inhibitor. The aim of this study was to evaluate the activity of C/T against clinical isolates of P. aeruginosa and Enterobacterales collected from five Latin American countries between 2016 and 2017, before its clinical use in Latin America, and to compare it with the activity of other available broad-spectrum antimicrobial agents. Methods: a total of 2760 clinical isolates (508 P. aeruginosa and 2252 Enterobacterales) were consecutively collected from 20 hospitals and susceptibility to C/T and comparator agents was tested and interpreted following the current guidelines. Results: according to the CLSI breakpoints, 68.1% (346/508) of P. aeruginosa and 83.9% (1889/2252) of Enterobacterales isolates were susceptible to C/T. Overall, C/T demonstrated higher in vitro activity than currently available cephalosporins, piperacillin/tazobactam and carbapenems when tested against P. aeruginosa, and its performance in vitro was comparable to fosfomycin. When tested against Enterobacterales, it showed higher activity than cephalosporins and piperacillin/tazobactam, and similar activity to ertapenem. Conclusions: these results show that C/T is an active β-lactam agent against clinical isolates of P. aeruginosa and Enterobacterales.
publishDate 2022
dc.date.none.fl_str_mv 2022-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/216748
García Betancur, Juan Carlos; De La Cadena, Elsa; Mojica, María F.; Hernández Gómez, Cristhian; Correa, Adriana; et al.; Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries; MDPI; Antibiotics; 11; 8; 8-2022; 1-11
2079-6382
CONICET Digital
CONICET
url http://hdl.handle.net/11336/216748
identifier_str_mv García Betancur, Juan Carlos; De La Cadena, Elsa; Mojica, María F.; Hernández Gómez, Cristhian; Correa, Adriana; et al.; Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries; MDPI; Antibiotics; 11; 8; 8-2022; 1-11
2079-6382
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3390/antibiotics11081101
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614017583153152
score 13.070432

Publicaciones similares